MAR 21·MarketBeat→
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research
Zacks Research has upgraded Theravance Biopharma (NASDAQ:TBPH) to a "Strong-Buy" rating. This upgrade comes after Theravance reported a Q4 beat with EPS of $1.15 and revenue of $45.9M, projecting approximately $400M in cash with no debt by end-Q1 2026 and significant cost savings. However, the company is also undergoing a restructuring, has discontinued a key pipeline candidate, and an SVP recently sold shares, leading to mixed analyst sentiment despite the recent upgrade.
MAR 20·Simply Wall Street▲
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base
Theravance Biopharma (TBPH) has transitioned to profitability in FY 2025, with a significant swing from a net loss to a US$105.9 million profit on improved revenue of US$107.5 million. While this supports bullish arguments regarding disciplined spending and potential new products, skeptics highlight the narrow revenue base, modest growth, and projected earnings decline, indicating that the company's long-term stability still needs to be proven beyond its reliance on a few key therapies. Both fair value and analyst price targets suggest the stock may be undervalued compared to peers, despite trading richer than the broader pharmaceuticals industry.
